ECDC reports ongoing chikungunya outbreaks, mostly in the Americas

Its October 5 overview records 197,497 cases and 87 associated deaths in the Americas, alongside locally acquired cases in France and Italy.

Its October 5 overview records 197,497 cases and 87 associated deaths in the Americas, alongside locally acquired cases in France and Italy.
Chikungunya virus disease outbreaks continued in several countries in 2026, with most of those countries in the Americas, according to ECDC’s October 5 overview. France and Italy also reported locally acquired cases— infections caught within those countries rather than abroad—through September.
| Region | Reported cases | Reported associated deaths |
|---|---|---|
| Americas | 197,497 | 87 |
| Asia | 45,633 | None reported |
| Africa | Approximately 6,921 | None reported |
ECDC reported 300 cases in Costa Rica in 2026, compared with eight in all of 2025. The agency described a significant increase in case reporting during the second half of August. Local transmission was reported in Alajuela and Guanacaste provinces.
For Bolivia, ECDC reported that the national case count had risen over the preceding weeks. Santa Cruz accounted for most of the country’s reported cases. Cochabamba, Tarija and La Paz were also among the most affected departments.
Brazil had the highest reported case count in the Americas: 127,676 by the end of epidemiological week 34, the surveillance week covering August 23–29. Cases continued to be reported in all five of Brazil’s regions.
India had Asia’s highest reported case count, according to ECDC. In August, another 167 cases were reported in Kerala state, mostly in the city of Thiruvananthapuram. Local authorities identified the monsoon season as the expected driver of that outbreak.
Mauritius accounted for most of Africa’s reported cases. ECDC recorded 6,891 cases since January on Mauritius Island and Rodrigues Island, with most on Mauritius Island.
Whether the worldwide case count has increased compared with earlier years, and what risk individual travellers face, remain unclear.

An AP investigation details evacuation delays, disputed hospital admission decisions and barriers to brain-injury diagnosis and follow-up treatment.
3 min

The $4.99-a-month service is limited to adults with mild-to-moderate acne. Nolla’s oversight plan moves from physician approval before prescriptions are issued to reviews afterward.
2 min

Epidemiologists point to advances in lung-cancer treatment and better dosing schedules for childhood leukaemia as two different routes to progress.
2 min